Designed and delivered by experts from industry and academia, this training event will provide a comprehensive overview of the pre-clinical drug discovery process. The workshop will focus on small molecule target identification and validation, hit-to-lead and lead optimisation, as well as on pre-clinical drug development and toxicology.
The programme will include lectures, case studies and group discussions, providing great networking opportunities and encouraging collaboration among delegates and speakers.
- Rick Davies, AstraZeneca
- Jacqui Piner, GSK
- John Unitt, Sygnature Discovery
- Heather Wallace, University of Aberdeen
- John Ladbury, University of Leeds
- John Colyer, University of Leeds